

26102452D

1 **HOUSE BILL NO. 1025**

2 Offered January 14, 2026

3 Prefiled January 14, 2026

4 *A BILL to amend and reenact §§ 54.1-3442.1, 54.1-3442.2, and 54.1-3442.3 of the Code of Virginia, relating*
5 *to access to investigational drugs, biological products, and devices; patient with severely debilitating*
6 *condition.*

7 Patron—Walker

8 Committee Referral Pending

9 **Be it enacted by the General Assembly of Virginia:**10 **1. That §§ 54.1-3442.1, 54.1-3442.2, and 54.1-3442.3 of the Code of Virginia are amended and reenacted**
11 **as follows:**12 **§ 54.1-3442.1. Definitions.**

13 As used in this article, unless the context requires a different meaning:

14 "Investigational drug, biological product, or device" means a drug, biological product, or device that has
15 successfully completed Phase I of a clinical trial but has not been approved for general use by the U.S. Food
16 and Drug Administration and remains under investigation in a clinical trial.

17 "Severely debilitating condition" means a disease or condition that causes major irreversible morbidity.

18 "Terminal condition" means a condition caused by injury, disease, or illness from which, to a reasonable
19 degree of medical probability, a patient cannot recover and (i) the patient's death is imminent or (ii) the
20 patient is in a persistent vegetative state.21 "Treating physician" means a physician who is providing or has previously provided medical treatment or
22 evaluation to and has or previously had an ongoing treatment relationship with the person.23 **§ 54.1-3442.2. Eligibility for expanded access to investigational drugs, biological products, and**
24 **devices; written, informed consent to treatment.**25 A. A person shall be eligible for expanded access to investigational drugs, biological products, or devices
26 if:27 1. He has a terminal or severely debilitating condition, attested to by his treating physician and confirmed
28 by a second physician not previously involved in the treatment of the person who has conducted an
29 independent examination of the person;30 2. He has, in consultation with his treating physician, considered all other treatment options currently
31 approved by the U.S. Food and Drug Administration and the treating physician has determined that no
32 reasonable opportunity exists for him to participate in an ongoing clinical trial for his terminal or severely
33 debilitating condition;34 3. The potential benefits of use of the investigational drug, biological product, or device to treat his
35 terminal or severely debilitating condition are greater than the potential risks of the use of the investigational
36 drug, biological product, or device to treat his terminal or severely debilitating condition;37 4. He has received a recommendation from his treating physician for use of an investigational drug,
38 biological product, or device for treatment of his terminal or severely debilitating condition; and39 5. He or, if he is incapable of making an informed decision, his legally authorized representative has given
40 written informed consent to use of the investigational drug, biological product, or device for treatment of his
41 terminal or severely debilitating condition or, if the person is a minor or lacks capacity to provide informed
42 consent, his parent or legal guardian has given written informed consent to the use of the investigational drug,
43 biological product, or device for treatment of his terminal or severely debilitating condition.44 Documentation indicating that the person meets the criteria for eligibility for expanded access to
45 investigational drugs, biological products, or devices shall be provided by the person's treating physician and
46 shall be included in the person's medical record.

47 B. Written informed consent to use of an investigational drug, biological product, or device shall include:

48 1. An explanation of the currently approved products and treatments for the person's terminal or severely
49 debilitating condition;50 2. A statement that the person has, in consultation with his treating physician, considered all other
51 treatment options currently approved by the U.S. Food and Drug Administration and the treating physician
52 has determined that no reasonable opportunity exists for the person to participate in an ongoing clinical trial
53 for his terminal or severely debilitating condition;54 3. An explanation of the specific investigational drug, biological product, or device proposed for treatment
55 of the person's terminal or severely debilitating condition;

56 4. A description of possible outcomes resulting from use of the investigational drug, biological product, or

INTRODUCED

HB1025

59 device to treat the person's terminal *or severely debilitating* condition, including a statement that new,
60 unanticipated, different, or worse symptoms might result from and death could be hastened by the proposed
61 treatment, based on the treating physician's knowledge of the proposed treatment in conjunction with an
62 awareness of the person's terminal *or severely debilitating* condition;

63 5. A statement that the person may be required to pay any costs associated with use of the investigational
64 drug, biological product, or device; and

65 6. A statement that the person or, if the person is a minor or lacks capacity to provide informed consent,
66 his parent or legal guardian consents to the use of the investigational drug, biological product, or device for
67 treatment of his terminal *or severely debilitating* condition.

68 **§ 54.1-3442.3. Expanded access to investigational drugs, biological products, or devices; cost;
69 insurance coverage.**

70 A. A manufacturer of an investigational drug, biological product, or device may make such investigational
71 drug, biological product, or device available to a person who meets the criteria set forth in subsection A of
72 § 54.1-3442.2; however, nothing in this article shall require a manufacturer of an investigational drug,
73 biological product, or device to make such investigational drug, biological product, or device available to
74 such person.

75 B. A manufacturer that makes an investigational drug, biological product, or device available to a person
76 who meets the criteria set forth in subsection A of § 54.1-3442.2 may provide the investigational drug,
77 biological product, or device to the person free of charge or may require the person to pay the costs of, or the
78 costs associated with, the manufacture of the investigational drug, biological product, or device.

79 C. An insurer proposing to issue individual or group accident and sickness insurance policies providing
80 hospital, medical and surgical, or major medical coverage on an expense-incurred basis, a corporation
81 providing individual or group accident and sickness subscription contracts, or a health maintenance
82 organization providing a health care plan for health care services may provide coverage for costs related to
83 treatment of a person's terminal *or severely debilitating* condition with an investigational drug, biological
84 product, or device; however, nothing in this article shall require an insurer proposing to issue individual or
85 group accident and sickness insurance policies providing hospital, medical and surgical, or major medical
86 coverage on an expense-incurred basis, a corporation providing individual or group accident and sickness
87 subscription contracts, or a health maintenance organization providing a health care plan for health care
88 services to provide coverage for costs related to treatment of a person's terminal *or severely debilitating*
89 condition with an investigational drug, biological product, or device.